Related Experiment Video
Updated: May 18, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Closed-loop insulin therapy improves glycemic control in children aged <7 years: a randomized controlled trial
Andrew Dauber1, Liat Corcia, Jason Safer
1Division of Endocrinology, Boston Children’s Hospital, Boston, MA, USA.
Insights
Closed-loop insulin therapy shows promise for improving overnight glucose control in young children with type 1 diabetes. This advanced system reduces hyperglycemia without increasing hypoglycemia, preparing them better for meals.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disease Research
- Diabetes Technology
Background:
- Type 1 diabetes management in young children presents unique challenges.
- Optimizing glycemic control is crucial for preventing long-term complications.
- Insulin pump therapy is a common treatment modality.
Purpose of the Study:
- To evaluate the efficacy of closed-loop insulin therapy in enhancing nocturnal glycemic control.
- To assess the impact of closed-loop therapy on meal glycemic response in children under 7 years old.
- To compare closed-loop with open-loop insulin pump therapy.
Main Methods:
- Randomized controlled crossover trial conducted in an inpatient setting.
- Ten children under 7 years with type 1 diabetes using insulin pumps participated.
- Comparison of closed-loop vs. standard open-loop therapy over 2 consecutive days, focusing on overnight and postprandial periods.
Main Results:
- Closed-loop therapy demonstrated a significant reduction in time spent with glucose levels >300 mg/dL overnight (P=0.035).
- A trend towards improved time in range (110-200 mg/dL) overnight was observed (P=0.12).
- Closed-loop therapy improved pre-meal glucose levels compared to open-loop (189 vs. 273 mg/dL, P=0.009) without increasing hypoglycemia.
Conclusions:
- Closed-loop insulin delivery effectively reduces overnight hyperglycemia in young children with type 1 diabetes.
- This therapy improves glucose normalization before subsequent meals.
- Young children with type 1 diabetes may benefit significantly from closed-loop systems.
Objective:
To assess the possibility of improving nocturnal glycemic control as well as meal glycemic response using closed-loop therapy in children aged <7 years.
Research Design And Methods:
This was a randomized controlled crossover trial comparing closed-loop with standard open-loop insulin pump therapy performed in an inpatient clinical research center. Ten subjects aged <7 years with type 1 diabetes for >6 months treated with insulin pump therapy were studied. Closed-loop therapy and standard open-loop therapy were compared from 10:00 p.m. to 12:00 p.m. on 2 consecutive days. The primary outcome was plasma glucose time in range (110-200 mg/dL) during the night (10:00 p.m.-8:00 a.m.). Secondary outcomes included peak postprandial glucose levels, incidence of hypoglycemia, degree of hyperglycemia, and prelunch glucose levels.
Results:
A trend toward a higher mean nocturnal time within target range was noted for closed- versus open-loop therapy, although not reaching statistical significance (5.3 vs. 3.2 h, P = 0.12). There was no difference in peak postprandial glucose or number of episodes of hypoglycemia. There was significant improvement in time spent >300 mg/dL overnight with closed-loop therapy (0.18 vs. 1.3 h, P = 0.035) and the total area under the curve of glucose >200 mg/dL (P = 0.049). Closed-loop therapy returned prelunch blood glucose closer to target (189 vs. 273 mg/dL on open loop, P = 0.009).
Conclusions:
Closed-loop insulin delivery decreases the severity of overnight hyperglycemia without increasing the incidence of hypoglycemia. The therapy is better able to reestablish target glucose levels in advance of a subsequent meal. Younger children with type 1 diabetes may reap significant benefits from closed-loop therapy.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Type I Diabetes I: Introduction
Pharmacokinetics in Pediatric Patients: Drug Metabolism
